2014
DOI: 10.1186/1471-2407-14-761
|View full text |Cite
|
Sign up to set email alerts
|

Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study results

Abstract: BackgroundTo evaluate the efficacy of first-line bevacizumab-based chemotherapy for untreated metastatic colorectal cancer (mCRC) based on age.MethodsEligibility criteria focused on M1 disease without prior palliative chemotherapy. Choice of chemotherapy regimen was at the physician’s discretion. Predefined efficacy endpoints were response rate, progression-free and overall survival (PFS, OS). Patients were analysed by age (<70 vs. ≥70 years, <75 vs. ≥75 years).ResultsOf 1777 patients, 27% and 12% were ≥70 and… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

3
23
0

Year Published

2015
2015
2021
2021

Publication Types

Select...
6
2
1

Relationship

0
9

Authors

Journals

citations
Cited by 16 publications
(26 citation statements)
references
References 21 publications
3
23
0
Order By: Relevance
“…(34) First-line bevacizumab based CTs were effective in patients > 75 years of age, however shorter PFS and OS was observed when compared to younger patients. (35) In our study, the Cox proportional hazard ratios showed that patients aged ≤ 50 years were more responsive to bevacizumab treatment than patients aged > 50 years. However, the current study does not draw any solid conclusion as only 20 patients out of 51 patients were aged ≤ 50 years.…”
Section: Discussionsupporting
confidence: 48%
“…(34) First-line bevacizumab based CTs were effective in patients > 75 years of age, however shorter PFS and OS was observed when compared to younger patients. (35) In our study, the Cox proportional hazard ratios showed that patients aged ≤ 50 years were more responsive to bevacizumab treatment than patients aged > 50 years. However, the current study does not draw any solid conclusion as only 20 patients out of 51 patients were aged ≤ 50 years.…”
Section: Discussionsupporting
confidence: 48%
“…After exclusion of duplicates and irrelevant studies, 8 reports were deemed to be eligible for the meta-analysis ( Figure 1). 13,[18][19][20][21][22][23][24] Of the 8 studies, 3 were multicenter RCTs (n ¼ 558) 13,18,19 and 5 were phase II or prospective series (n ¼ 224). [20][21][22][23][24] The characteristics of the studies included are reported in Supplemental Table 1 (available in the online version).…”
Section: Published Data Search Results and Study Populationmentioning
confidence: 99%
“…13,[18][19][20][21][22][23][24] Of the 8 studies, 3 were multicenter RCTs (n ¼ 558) 13,18,19 and 5 were phase II or prospective series (n ¼ 224). [20][21][22][23][24] The characteristics of the studies included are reported in Supplemental Table 1 (available in the online version). Patient age for inclusion was 70 or 75 years in 5 studies 13,[20][21][22][23] and 2 studies, 18,24 respectively, and 65 years in 1 trial.…”
Section: Published Data Search Results and Study Populationmentioning
confidence: 99%
“…PFS in the elderly patients was similar to their younger counterparts though median OS declined with increasing age [47] . Interestingly however, in another large observational cohort study of 1777 treatmentnaive German mCRC patients, those ≥ 75 years of age had a significantly lower PFS and median OS when compared to those < 75 years of age (PFS: 10.5 mo vs 8.9 mo; P = 0.00019; OS: 25.8 mo vs 20.8 mo; P < 0.0001) [48] . In a multicenter phase Ⅱ study by the Hellenic Oncology Research Group, the combination of capecitabine, oxaliplatin, and bevacizumab (AVELOX) was proven to be safe and effective in the first-line treatment of elderly patients (≥ 70 years old) [49] .…”
Section: Bevacizumab-based Chemotherapy In the Elderlymentioning
confidence: 92%